Importer of Controlled Substances; Notice of Registration; Fisher Clinical Services, Inc., 5497 [2013-01532]
Download as PDF
Federal Register / Vol. 78, No. 17 / Friday, January 25, 2013 / Notices
Zhou Licheng, No. 45, Miaotou Natural
Village, Qianjia Administrative
Village, Yaoguan Town, Wujin
District, Changzhou City, Jiangsu
Province, China, 213102;
Randall Graves, Apartment 1201, Unit
C, Block 320, Nandu Section, Hutang
New City Complex, Wujin District,
Changzhou City, Jiangsu Province,
China, 213161;
‘‘Jessica’’ Wang Chongge, Group 1,
Tonguyan Village, Tongyuan Town,
Gaoling County, Xi’an City, Shaanzi
Province, China 710202.
mstockstill on DSK4VPTVN1PROD with
(c) The Office of Unfair Import
Investigations, U.S. International Trade
Commission, 500 E Street SW., Suite
401, Washington, DC 20436; and
(3) For the investigation so instituted,
the Chief Administrative Law Judge,
U.S. International Trade Commission,
shall designate the presiding
Administrative Law Judge.
Responses to the complaint and the
notice of investigation must be
submitted by the named respondents in
accordance with section 210.13 of the
Commission’s Rules of Practice and
Procedure, 19 CFR 210.13. Pursuant to
19 CFR 201.16(d)–(e) and 210.13(a),
such responses will be considered by
the Commission if received not later
than 20 days after the date of service by
the Commission of the complaint and
the notice of investigation. Extensions of
time for submitting responses to the
complaint and the notice of
investigation will not be granted unless
good cause therefor is shown.
Failure of a respondent to file a timely
response to each allegation in the
complaint and in this notice may be
deemed to constitute a waiver of the
right to appear and contest the
allegations of the complaint and this
notice, and to authorize the
administrative law judge and the
Commission, without further notice to
the respondent, to find the facts to be as
alleged in the complaint and this notice
and to enter an initial determination
and a final determination containing
such findings, and may result in the
issuance of an exclusion order or a cease
and desist order or both directed against
the respondent.
By order of the Commission.
Issued: January 22, 2013.
William R. Bishop,
Supervisory Hearings and Information
Officer.
[FR Doc. 2013–01553 Filed 1–24–13; 8:45 am]
BILLING CODE 7020–02–P
VerDate Mar<15>2010
18:39 Jan 24, 2013
Jkt 229001
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances;
Notice of Registration; Fisher Clinical
Services, Inc.
By Notice dated November 1, 2012,
and published in the Federal Register
on November 9, 2012, 77 FR 67396,
Fisher Clinical Services, Inc., 7554
Schantz Road, Allentown, Pennsylvania
18106, made application to the Drug
Enforcement Administration (DEA) to
be registered as an importer of
Tapentadol (9780), a basic class of
controlled substance listed in schedule
II.
The company plans to import the
listed controlled substance to conduct
clinical trials.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and 952(a),
and determined that the registration of
Fisher Clinical Services, Inc., to import
the basic class of controlled substance is
consistent with the public interest, and
with United States obligations under
international treaties, conventions, or
protocols in effect on May 1, 1971. DEA
has investigated Fisher Clinical
Services, Inc., to ensure that the
company’s registration is consistent
with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C.
952(a) and 958(a), and in accordance
with 21 CFR 1301.34, the above named
company is granted registration as an
importer of the basic class of controlled
substance listed.
Dated: January 16, 2013.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2013–01532 Filed 1–24–13; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances;
Notice of Application
Pursuant to 21 U.S.C. 958(i), the
Attorney General shall, prior to issuing
a registration under this Section to a
bulk manufacturer of a controlled
substance in schedules I or II, and prior
to issuing a regulation under 21 U.S.C.
PO 00000
Frm 00091
Fmt 4703
Sfmt 9990
5497
952(a)(2) authorizing the importation of
such a substance, provide
manufacturers holding registrations for
the bulk manufacture of the substance
an opportunity for a hearing.
Therefore, in accordance with 21 CFR
1301.34(a), this is notice that on
September 21, 2012, Nebraska State
Penitentiary, 4201 South 14th Street,
Lincoln, Nebraska 68502, made
application to the Drug Enforcement
Administration (DEA) to be registered as
an importer of Pentobarbital (2270), a
basic class of controlled substance listed
in schedule II.
The facility intends to import the
above listed controlled substance for
legitimate use. Supplies of this
particular controlled substance are
inadequate and are not available in the
form needed within the current
domestic supply of the United States.
Any bulk manufacturer who is
presently, or is applying to be,
registered with DEA to manufacture
such basic class of controlled substance
may file comments or objections to the
issuance of the proposed registration,
and may, at the same time, file a written
request for a hearing on such
application pursuant to 21 CFR 1301.43,
and in such form as prescribed by 21
CFR 1316.47.
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than February 25, 2013.
This procedure is to be conducted
simultaneously with, and independent
of, the procedures described in 21 CFR
1301.34(b), (c), (d), (e), and (f). As noted
in a previous notice published in the
Federal Register on September 23, 1975,
40 FR 43745–46, all applicants for
registration to import a basic class of
any controlled substance in schedule I
or II are, and will continue to be,
required to demonstrate to the Deputy
Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration, that the requirements
for such registration pursuant to 21
U.S.C. 958(a), 21 U.S.C. 823(a), and 21
CFR 1301.34(b), (c), (d), (e), and (f) are
satisfied.
Dated: January 16, 2013.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2013–01536 Filed 1–24–13; 8:45 am]
BILLING CODE 4410–09–P
E:\FR\FM\25JAN1.SGM
25JAN1
Agencies
[Federal Register Volume 78, Number 17 (Friday, January 25, 2013)]
[Notices]
[Page 5497]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-01532]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances; Notice of Registration; Fisher
Clinical Services, Inc.
By Notice dated November 1, 2012, and published in the Federal
Register on November 9, 2012, 77 FR 67396, Fisher Clinical Services,
Inc., 7554 Schantz Road, Allentown, Pennsylvania 18106, made
application to the Drug Enforcement Administration (DEA) to be
registered as an importer of Tapentadol (9780), a basic class of
controlled substance listed in schedule II.
The company plans to import the listed controlled substance to
conduct clinical trials.
No comments or objections have been received. DEA has considered
the factors in 21 U.S.C. 823(a) and 952(a), and determined that the
registration of Fisher Clinical Services, Inc., to import the basic
class of controlled substance is consistent with the public interest,
and with United States obligations under international treaties,
conventions, or protocols in effect on May 1, 1971. DEA has
investigated Fisher Clinical Services, Inc., to ensure that the
company's registration is consistent with the public interest. The
investigation has included inspection and testing of the company's
physical security systems, verification of the company's compliance
with state and local laws, and a review of the company's background and
history.
Therefore, pursuant to 21 U.S.C. 952(a) and 958(a), and in
accordance with 21 CFR 1301.34, the above named company is granted
registration as an importer of the basic class of controlled substance
listed.
Dated: January 16, 2013.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. 2013-01532 Filed 1-24-13; 8:45 am]
BILLING CODE 4410-09-P